|Mr. Erik T. Engelson||Pres, CEO & Director||369.69k||N/A||1960|
|Dr. Debkishore Mitra Ph.D.||CTO & Director||311.35k||N/A||1987|
|Mr. Daniel V. George||CFO & Treasurer||N/A||N/A||1970|
|Mr. Tony Allen||Chief Operations Officer||N/A||N/A||N/A|
|Greg Chodaczek||Investor Relations||N/A||N/A||N/A|
|Mr. Kevin Walter Collins||Chief Revenue Officer||N/A||N/A||N/A|
|Mr. Ghazi Kashmolah||Chief Quality Officer & Exec. VP of Regulatory Affairs||N/A||N/A||N/A|
|Ms. Tamanna Prashar||VP of Global Supply Chain, Operations & Quality||N/A||N/A||1981|
Lucira Health, Inc., a medical technology company, focuses on the development and commercialization of infectious disease test kits. It develops a testing platform that produces molecular testing services. The company offers LUCIRA COVID-19 All-In-One Test Kit, a COVID-19 test kit; and develops influenza A and B viruses test kits. It has a patent license agreement with Eiken Chemical Co., Ltd.; technical services agreement with Jabil, Inc.; and manufacturing services agreement with Jabil MSA. The company was formerly known as DiAssess Inc. and changed its name to Lucira Health, Inc. in January 2020. Lucira Health, Inc. was incorporated in 2013 and is headquartered in Emeryville, California.
Lucira Health, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.